GENA-104 ADC
Stage unconfirmedAn ADC directed at CNTN4, a novel target found with GNOCLE.
FROM PUBLIC EVENTS · 2026-11-18
Discovery · preclinical After licensing a novel-target antibody, it is extending research into ADC candidates against the same and other new targets. Also seen: Early clinical · first deals
Roles often seen at this stageResearch & development · BD & licensing · Data & AI
Develops immuno-oncology antibodies and antibody-drug conjugates (ADCs) against novel targets found with its GNOCLE discovery platform.
An ADC directed at CNTN4, a novel target found with GNOCLE.
GENA-120 is an ITGB4-targeted ADC; GENB-120 is a bispecific ADC targeting ITGB4 and TROP2.
A CNTN4-targeted immuno-oncology antibody licensed to UK-based Ellipses Pharma in February 2025.
Announced it would present research data on its novel-target ADC pipeline and hold partnering meetings at World ADC San Diego.
Licensed the novel-target immuno-oncology candidate GENA-104 to Ellipses Pharma (UK).
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.